Login to Your Account

Clinic Roundup

Tuesday, November 22, 2011
• Celldex Therapeutics Inc., of Needham, Mass., presented Phase II data showing rindopepimut (CDX-110) resulted in final overall survival of 24.6 months from diagnosis of EGFRvIII-positive glioblastoma, compared to 15.2 months for a historic control.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription